For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Topiramate - Migraine (prevention)
PAD Profile : Topiramate - Migraine (prevention) Important
Traffic Light Status
Status 1 of 3.
- Tablets
Status 2 of 3.
- Capsules
Status 3 of 3.
- Oral suspension
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System (ICS) Area Prescribing Committee has agreed a GREEN traffic light status for topiramate (prescribed generically), for migraine prophylaxis in line with NICE Clinical Knowledge Summaries (CKS). Note that topiramate is contraindicated in pregnancy.
Topiramate tablets
If indicated for women and girls of childbearing age ensure that a pregnancy prevention plan (PPP) is in place.
Topiramate capsules
Only use in patients who cannot swallow tablets and ensure that a PPP is in place for women and girls of childbearing age.
Topiramate liquid
Only use in patients who cannot swallow tablets or capsules and ensure that a PPP is in place for women and girls of childbearing age.
Information in CKS is available by following this link https://cks.nice.org.uk/topics/migraine/prescribing-information/drugs-for-the-prevention-of-migraine/